‘Global Anti-Epilepsy Drugs Market Worth $5.1bn In 2021’ Says Visiongain Report

20 August 2018
Pharma

Visiongain’s new report Global Anti-Epilepsy Drugs Market Forecast 2017-2027: first-generation drugs, second-generation drugs, third-generation drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin indicates that the global anti-epilepsy drugs market will see $5.1bn in spending in 2021.
The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

The lead analyst of the report said: “In 2016, the global Anti-Epilepsy Drugs Market was valued at $4.3bn. The market is anticipated to grow at a CAGR of 4.4% to reach $6.9bn in 2027. Currently, the market is dominated by second-generation drugs. However, third-generation drugs are set to see the fastest growth during forecast period.

In 2016, the Epilepsy market was dominated by the US with a share of 47.5%. The market is expected to experience a high growth rate because of the increasing number of epilepsy patients in this region and increasing initiatives by the CDC to manage epilepsy.”

The 145-page report contains 100 charts that add visual analysis in order to explain the developing trends within the Global Anti-Epilepsy Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs and Others. This report also discusses the leading anti-epilepsy drugs and selected pipeline molecules.

The 145-page report offers market forecasts and analysis for the US, Japan, EU5, BRIC and RoW. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the anti-epilepsy drugs market. Moreover, this report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK. This report also covers pricing and reimbursement overview of the anti-epilepsy drugs market

The Global Anti-Epilepsy Drugs Market Forecast 2017-2027: first-generation drugs, second-generation drugs, third-generation drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin report will be of value to anyone who wants to better understand the anti-epilepsy drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the anti-epilepsy drugs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever